Real-World Effectiveness and Safety of Tixagevimab–Cilgavimab: A Target Trial Emulation Study-Reference-Cited by-同舟云学术

Real-World Effectiveness and Safety of Tixagevimab–Cilgavimab: A Target Trial Emulation Study

Published:2024-06-25 Issue:10 Volume:47 Page:1025-1037
ISSN:0114-5916
Container-title:Drug Safety
language:en
Short-container-title:Drug Saf

Author:

Yan Vincent Ka Chun,Yang Yu,Wan Eric Yuk Fai,Lai Francisco Tsz Tsun,Chui Celine Sze Ling,Li Xue,Wong Carlos King Ho,Hung Ivan Fan Ngai,Lau Chak Sing,Wong Ian Chi Kei,Chan Esther Wai Yin^ORCID

Funder

HMRF Research on COVID-19

Publisher

Springer Science and Business Media LLC

Link

https://link.springer.com/content/pdf/10.1007/s40264-024-01450-4.pdf

Reference39 articles.

1. Williamson EJ, Walker AJ, Bhaskaran K, et al. Factors associated with COVID-19-related death using OpenSAFELY. Nature. 2020;584(7821):430–6. https://doi.org/10.1038/s41586-020-2521-4.

2. Monin L, Laing AG, Munoz-Ruiz M, et al. Safety and immunogenicity of one versus two doses of the COVID-19 vaccine BNT162b2 for patients with cancer: interim analysis of a prospective observational study. Lancet Oncol. 2021;22(6):765–78. https://doi.org/10.1016/S1470-2045(21)00213-8.

3. Qin CX, Moore LW, Anjan S, et al. Risk of breakthrough SARS-CoV-2 infections in adult transplant recipients. Transplantation. 2021;105(11):e265–6. https://doi.org/10.1097/TP.0000000000003907.

4. Khan N, Mahmud N. Effectiveness of SARS-CoV-2 vaccination in a veterans affairs cohort of patients with inflammatory bowel disease with diverse exposure to immunosuppressive medications. Gastroenterology. 2021;161(3):827–36. https://doi.org/10.1053/j.gastro.2021.05.044.

5. Simon B, Rubey H, Treipl A, et al. Haemodialysis patients show a highly diminished antibody response after COVID-19 mRNA vaccination compared with healthy controls. Nephrol Dial Transpl. 2021;36(9):1709–16. https://doi.org/10.1093/ndt/gfab179.